# US 2024/0189280 A1 · Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189280 A1
- Document ID: US20240189280A1
- Status: Published application
- Kind: A1
- Application number: 18/538,443
- Filed: 2023-12-13
- Published: 2024-06-13
- Earliest claimed: 2019-11-20
- Assignees: Ji Xing Pharmaceuticals Hong Kong Limited
- Applicants: Ji Xing Pharmaceuticals Hong Kong Limited
- Inventors: Teiji TOMINAGA; Kuniyasu Niizuma
- Web page: https://patentgrep.com/patent/US20240189280A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:

## Claims

### Claim 1

A drug used for treating or preventing cerebral hemorrhage, the drug comprising, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein, in Formula (I), L represents an aliphatic hydrocarbon group having from 4 to 10 carbon atoms, X represents a hydroxy group or a carboxy group, n represents an integer from 0 to 2, and R represents a hydrogen atom or a substituent having a molecular weight of 1000 or less.

### Claim 2 (depends on 1)

The drug according to claim 1, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is a compound represented by the following Formula (IA) or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein, in Formula (IA), X is —CHY—C(CH3)2Z, wherein each of Y and Z is independently —H or —OH, or Y and Z together form a single bond, and R represents a hydrogen atom or a substituent having a molecular weight of 1,000 or less.

### Claim 3 (depends on 1)

The drug according to claim 1, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is a compound represented by the following Formula (II) or Formula (III), or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein, in Formula (II) or Formula (III), each of X1, X2, and X3 is independently —CHY—C(CH3)2Z, wherein each of Y and Z is independently —H or —OH, or Y and Z together form a single bond, and IV represents any one of the following (A) to (D):
(A) a residue (provided that —(CH)2-OH is excluded) obtained by removing one amino group from an amino compound selected from the group consisting of: a natural amino acid; a D-isomer of a natural amino acid; and a compound in which at least one carboxy group in a natural amino acid or a D-isoform of a natural amino acid is substituted with a hydrogen atom, a hydroxy group, or a hydroxymethyl group;
(B) an aromatic group having at least one selected from the group consisting of a carboxy group, a hydroxy group, a sulfonic acid group, and a secondary amino group as a substituent or as a part of a substituent; or an aromatic group that includes a secondary amino group and may include a nitrogen atom;
(C) an aromatic amino acid residue represented by the following Formula (II-1):
wherein, R3 is a substituent that may or may not be present, and if present, represents a hydroxy group, a carboxy group, or an alkyl group having from 1 to 5 carbon atoms, n represents an integer of 0 or 1, m represents an integer from 0 to 5, and * represents a bonding site; and
(D) a substituent represented by wherein -L1-L2-R4, represents a linking group that is an alkylene group having from 1 to 4 carbon atoms and including a carboxy group, L2 represents a linking group represented by —NH—C(=O)— or —NH—C(=S)—NH—, and R4 represents a 9-fluorenylalkyloxy group that includes an alkyloxy group having from 1 to 3 carbon atoms, or a polyheterocyclic group represented by the following Formula (II-2) (in Formula (II-2), * represents a bonding site):
wherein, R2 represents a residue obtained by removing two amino groups from an amino compound selected from the group consisting of: a natural amino acid including two amino groups; a D-isoform of a natural amino acid including two amino groups; a compound in which at least one carboxy group of a natural amino acid including two amino groups or a D-isoform of a natural amino acid including two amino groups is substituted with a hydrogen atom, a hydroxy group, or a hydroxymethyl group; a compound represented by H2N—CH(COOH)—(CH2)n-NH2 (wherein n is an integer from 0 to 9); and a compound represented by H2N—CH(COOH)—(CH2)m-Sp-(CH2)q-CH(COOH)—NH2 (wherein each of m, p, and q is independently an integer from 0 to 9).

### Claim 4 (depends on 1)

The drug according to claim 1, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is a compound selected from the group consisting of the following SMTP-0, SMTP-1, SMTP-4, SMTP-5D, SMTP-6, SMTP-7, SMTP-8, SMTP-11 to SMTP-14, SMTP-18 to SMTP-29, SMTP-36, SMTP-37, SMTP-42, SMTP-43, SMTP-43D, SMTP-44, SMTP-44D, SMTP-46, and SMTP-47, or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein * represents a bonding site.

### Claim 5 (depends on 4)

The drug according to claim 4, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is SMTP-7 or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 6 (depends on 1)

The drug according to claim 1, wherein the cerebral hemorrhage is intracerebral hemorrhage.

### Claim 7 (depends on 1)

The drug according to claim 1, which is administered intracerebrally.

### Claim 8

A method of treating a cerebral hemorrhage in a subject, the method comprising administering a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, in an amount effective for treating the cerebral hemorrhage, to the subject suffering from the cerebral hemorrhage:
wherein, in Formula (I), L represents an aliphatic hydrocarbon group having from 4 to 10 carbon atoms, X represents a hydroxy group or a carboxy group, n represents an integer from 0 to 2, and R represents a hydrogen atom or a substituent having a molecular weight of 1,000 or less.

### Claim 9

A method of preventing a cerebral hemorrhage in a subject, the method comprising administering a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, in an amount effective for preventing cerebral hemorrhage, to the subject at risk of developing cerebral hemorrhage:
wherein, in Formula (I), L represents an aliphatic hydrocarbon group having from 4 to 10 carbon atoms, X represents a hydroxy group or a carboxy group, n represents an integer from 0 to 2, and R represents a hydrogen atom or a substituent having a molecular weight of 1,000 or less.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is a compound represented by the following Formula (IA) or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein, in Formula (IA), X is —CHY—C(CH3)2Z, wherein each of Y and Z is independently —H or —OH, or Y and Z together form a single bond, and R represents a hydrogen atom or a substituent having a molecular weight of 1,000 or less.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is a compound represented by the following Formula (II) or Formula (III), or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein, in Formula (II) or Formula (III), each of X1, X2, and X3 is independently —CHY—C(CH3)2Z, wherein each of Y and Z is independently —H or —OH, or Y and Z together form a single bond, and R1 represents any one of the following (A) to (D):
(A) a residue (provided that —(CH)2-OH is excluded) obtained by removing one amino group from an amino compound selected from the group consisting of: a natural amino acid; a D-isoform of a natural amino acid; and a compound in which at least one carboxy group in a natural amino acid or a D-isoform of a natural amino acid is substituted with a hydrogen atom, a hydroxy group, or a hydroxymethyl group;
(B) an aromatic group having at least one selected from the group consisting of a carboxy group, a hydroxy group, a sulfonic acid group, and a secondary amino group as a substituent or as part of a substituent; or an aromatic group that includes a secondary amino group and may include a nitrogen atom;
(C) an aromatic amino acid residue of the following Formula (II-1):
wherein, each R3 is independently a substituent that may or may not be present, and if present, represents a hydroxy group, a carboxy group, or an alkyl group having from 1 to 5 carbon atoms, n represents an integer of 0 or 1, m represents an integer from 0 to 5, and * represents a bonding site; and
(D) a substituent represented by wherein -L1-L2-R4, wherein L1 represents a linking group that is an alkylene group having from 1 to 4 carbon atoms and including a carboxy group, L2 represents a linking group represented by —NH—C(=O)— or —NH—C(=S)—NH—, and R4 represents a 9-fluorenylalkyloxy group that includes an alkyloxy group having from 1 to 3 carbon atoms, or a polyheterocyclic group represented by the following Formula (II-2) (in Formula (II-2), * represents a bonding site):
wherein R2 represents a residue obtained by removing two amino groups from an amino compound selected from the group consisting of: a natural amino acid including two amino groups; a D-isoform of a natural amino acid including two amino groups; a compound in which at least one carboxy group of a natural amino acid including two amino groups or a D-isoform of a natural amino acid including two amino groups is substituted with a hydrogen atom, a hydroxy group, or a hydroxymethyl group; a compound represented by H2N—CH(COOH)—(CH2)n-NH2 (wherein n is an integer from 0 to 9); and a compound represented by H2N—CH(COOH)—(CH2)m-Sp-(CH2)q-CH(COOH)—NH2 (wherein each of m, p, and q is independently an integer from 0 to 9).

### Claim 12 (depends on 8)

The method according to claim 8, wherein the compound represented by Formula (I) or the pharmaceutically acceptable salt, ester, or solvate thereof is a compound selected from the group consisting of the following SMTP-0, SMTP-1, SMTP-4, SMTP-5D, SMTP-6, SMTP-7, SMTP-8, SMTP-11 to SMTP-14, SMTP-18 to SMTP-29, SMTP-36, SMTP-37, SMTP-42, SMTP-43, SMTP-43D, SMTP-44, SMTP-44D, SMTP-46, and SMTP-47, or a pharmaceutically acceptable salt, ester, or solvate thereof:
wherein * represents a bonding site.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is SMTP-7 or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 14 (depends on 8)

The method according to claim 8, wherein the cerebral hemorrhage is intracerebral hemorrhage.

### Claim 15 (depends on 8)

The method according to claim 8, wherein the compound represented by Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof is administered intracerebrally.
